Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, placebo-controlled, double-blind Phase 1b/2 study of U3-1287 (AMG 888) plus erlotinib in EGFR treatment-naive advanced NSCLC after prior chemotherapy
2010-021082-74Phase 2Completed
- Sponsor
- Daiichi Sankyo Development
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing U3-1287 + erlotinib with Placebo + erlotinib (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jul 2010; status: completed.
02
Drugs
patritumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-021082-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021082-74.